CT identified wooden foreign material in 9 of 30 dogs with acute oropharyngeal stick injuriesZoetis wins USDA license for 75-day canine allergy injectableHABRI study finds 36% of pet owners use AI for symptom interpretation before vet visitsNC State tracks 50 paralyzed dogs through medical management without surgeryAVMA publishes second antimicrobial stewardship report with species-specific pathogen summariesMycoplasma species detected in 46.9% of cats with respiratory signs in seven-year Czech studyCovetrus Says It Will Fight FTC Suit Blocking MWI Merger in CourtUtah State launches two-year vet tech program with online-plus-clinical modelCT identified wooden foreign material in 9 of 30 dogs with acute oropharyngeal stick injuriesZoetis wins USDA license for 75-day canine allergy injectableHABRI study finds 36% of pet owners use AI for symptom interpretation before vet visitsNC State tracks 50 paralyzed dogs through medical management without surgeryAVMA publishes second antimicrobial stewardship report with species-specific pathogen summariesMycoplasma species detected in 46.9% of cats with respiratory signs in seven-year Czech studyCovetrus Says It Will Fight FTC Suit Blocking MWI Merger in CourtUtah State launches two-year vet tech program with online-plus-clinical model
The U.S. Department of Agriculture "licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs," Zoetis announced. According to Zoetis, the monoclonal antibody "is administered by subcutaneous injection every 75 days as needed," which the company reports is "the longest dosing interval among licensed mAb treatments for canine allergic dermatitis." Zoetis stated that "Cytopoint Plus targets and neutralizes interleukin-31 (IL-31), a molecule involved in transmitting itch signals in dogs with allergic dermatitis."
The company's "existing dermatology portfolio includes Cytopoint and the oral medications Apoquel and Apoquel Chewable," according to Zoetis. The company did not disclose pricing or availability timing in the announcement.
The visit-frequency question every practice has to model
The 75-day interval means fewer required visits compared to shorter dosing protocols. Whether that helps or hurts a practice depends on three things: how the longer-acting product is priced relative to the shorter one, whether the extended interval improves compliance enough to keep more dogs in treatment long-term, and what happens to the appointment slots the derm rechecks were filling.
How Zoetis prices Cytopoint Plus will determine whether the longer interval preserves annual revenue per patient or trades visit frequency for convenience at a margin cost. The per-injection price and the total annual cost structure matter, and neither is public yet. Our read: practices that run high derm caseloads need to model this before the product launches, because revenue changes if fewer visits per patient doesn't pull in enough new compliant cases to offset the frequency drop.
"Frequent vet clinic visits for treating allergic dermatitis can create scheduling hurdles for busy pet caregivers, which may contribute to missed treatments and flare-ups," Lindsay McKay, DVM, DACVD, at Animal Dermatology Group said in a statement to Zoetis. "Cytopoint Plus directly addresses this challenge, extending the duration of relief from allergic itch through a manageable, convenient treatment routine."
Zoetis stated that the extended interval may "reduce treatment-related stress for dogs that find frequent veterinary visits difficult." The company also said the product may "provide veterinary teams with another option when developing individualized treatment plans, including for families managing the ongoing costs and logistics of chronic allergic dermatitis care."
The compliance argument is real for the subset of clients who skip appointments because frequent visits are a scheduling burden, not because they question the value. For clients who are cost-sensitive or skeptical of ongoing treatment, fewer required visits does not solve the underlying objection. It just spreads the decision points farther apart, and a client who drops out early is harder to recover than one who misses an appointment in an ongoing protocol.
The protocol update and the inventory question
If a practice stocks existing dermatology products now and clients start asking for the 75-day option, the decision is whether to carry both or phase out the shorter-interval product. Carrying both means managing multiple SKUs in the same category. Phasing out a shorter-interval product means betting the longer interval becomes the standard, and working through whatever stock is on hand.
We'd update standing derm protocols before the product launches so associate DVMs and front desk staff know which option to offer and under what circumstances. The worst outcome is inconsistent recommendations across doctors in the same practice, because that reads to the client as uncertainty about whether the new product is actually better.
The failure mode
The risk is that the longer interval reduces visit frequency without improving total case retention, and Zoetis prices the product in a way that leaves practices with lower annual revenue per derm patient. If the extended interval does not pull in enough new compliant cases to offset fewer visits per patient, the trade is a higher-frequency revenue stream for a lower one, and the convenience given to the client cost the practice.
The other risk is adopting the 75-day protocol practice-wide without modeling what it does to a derm caseload's contribution to fixed costs. Reducing visit frequency without replacing those appointment slots with something else that covers overhead can drop revenue per doctor per day even if per-patient margin holds.
Get the next issue in your inbox. Free, weekly, no fluff.